OMNIX Tablets / DT / Dry Syrup (Cefixime)

Table of Content

Qualitative and Quantitative Composition

OMNIX-50 DT

Each uncoated dispersible tablet contains:

Cefixime, IP, as a trihydrate equivalent to

anhydrous Cefixime ……………. 50 mg

In a flavoured base

Colour: Lake Quinoline Yellow WS

OMNIX-100 DT

Each uncoated dispersible tablet contains:

Cefixime, IP, as a trihydrate equivalent to

anhydrous Cefixime ……………. 100 mg

In a flavoured base

Colour: Lake Quinoline Yellow WS

OMNIX-200 DT

Each uncoated dispersible tablet contains:

Cefixime, IP, as a trihydrate equivalent to

anhydrous Cefixime ……………. 200 mg

In a flavoured base

Colour: Lake Quinoline Yellow WS

OMNIX-50 Dry Syrup

Each 5 mL (after reconstitution) contains:

Cefixime, IP, as a trihydrate equivalent to

anhydrous Cefixime ……………. 50 mg

OMNIX-100 Dry Syrup

Each 5 mL (after reconstitution) contains:

Cefixime IP as a trihydrate equivalent to

anhydrous Cefixime ……………. 100 mg

Dosage Form(S) and Strength(S)

50mg ,100mg, and 200mg Dispersible tablet and 50mg & 100mg dry powder for oral suspension

Clinical Particulars

Therapeutic Indications

To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefixime and other antibacterial drugs, cefixime should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.

When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

OMNIX DT/Dry Syrup is indicated in the treatment of adults and paediatric patients, 6 months of age or older, with the following infections when caused by susceptible isolates of the designated bacteria:

  • Uncomplicated urinary tract infections (e.g. cystitis, cystourethritis, uncomplicated pyelonephritis) caused by Escherichia coli and Proteus mirabilis.
  • Otitis media caused by Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pyogenes.
  • Note: For patients with otitis media caused by Streptococcus pneumoniae, overall response was approximately 10% lower for cefixime than for the comparator.
  • Pharyngitis and tonsillitis caused by Streptococcus pyogenes.
  • Note: Penicillin is the usual drug of choice in the treatment of Streptococcus pyogenes infections. Cefixime is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, data establishing the efficacy of cefixime in the subsequent prevention of rheumatic fever is not available.
  • Acute exacerbations of chronic bronchitis caused by Streptococcus pneumoniae and Haemophilus influenzae.
  • Uncomplicated gonorrhoea (cervical/urethral) caused by Neisseria gonorrhoeae (penicillinase- and non-penicillinase-producing isolates).
  • For the treatment of enteric (typhoid) fever.

Posology and Method of Administration

Adults

The recommended adult dosage is 200–400 mg daily according to the severity of infection, given either as a single dose or in two divided doses.

For the treatment of uncomplicated cervical/urethral gonococcal infections, a single oral dose of 400 mg is recommended. In the treatment of infections due to Streptococcus pyogenes, a therapeutic dosage of cefixime should be administered for at least 10 days.

Paediatric Patients (Aged 6 Months or Older)

The recommended dose is 8 mg/kg/day of the suspension. This may be administered as a single daily dose or may be given in two divided doses, as 4 mg/kg every 12 hours.

A suggested dose has been determined for each paediatric weight range in the table below.

Suggested Doses for Paediatric Patients

Paediatric Dosage Chart

Doses are suggested for each weight range and rounded for ease of administration

 

OMNIX Dry Syrup

50 mg/5 mL

100 mg/5 mL

Patient Weight (kg)

Dose/Day (mg)

Dose/Day

(mL)

Dose/Day

(mL)

5–7.5

50

5

2.5

7.6–10

80

8

4

10.1–12.5

100

10

5

12.6–20.5

150

15

7.5

20.6–28

200

20

10

28.1–33

250

--

12.5

33.1–40

300

--

15

40.1–45

350

--

17.5

45.1 or greater

400

--

20

OMNIX-50 Dry Syrup may be substituted with OMNIX-50 DT.

Children weighing more than 45 kg or older than 12 years should be treated with the recommended adult dose of 200–400 mg daily, depending on the severity of infection).

Otitis media should be treated with the suspension.

In the treatment of infections due to Streptococcus pyogenes, a therapeutic dosage of cefixime should be administered for at least 10 days.

The safety and efficacy of cefixime has not been established in children aged less than 6 months.

Geriatric Patients

Elderly patients may be given the same dose as recommended for adults. Renal function should be assessed and dosage should be adjusted in severe renal impairment.

Patients with Renal Impairment

Cefixime may be administered in the presence of impaired renal function. Normal dose and schedule may be given in patients with creatinine clearances of 20 mL/min or greater. In patients whose creatinine clearance is less than 20 mL/min, it is recommended that a dose of 200 mg once daily should not be exceeded. The dose and regimen for patients who are maintained on chronic ambulatory peritoneal dialysis (CAPD) or haemodialysis should follow the same recommendation as that for patients with creatinine clearances of less than 20 mL/min.

The usual course of treatment is 7 days. This may be continued for up to 14 days if required.

Administration

Absorption of OMNIX DT/Dry Syrup is not significantly modified by the presence of food.

OMNIX DT

Disperse the tablet in a teaspoonful (5 mL) of boiled and cooled water before administration.

OMNIX Dry Syrup

Directions for Preparing the Suspension

At the time of dispensing, the dry powder should be reconstituted to form an oral suspension. First, shake the bottle to loosen the powder. Twist and open the vial of sterile water given with the pack. Slowly add half the quantity of the sterile water into the bottle. Recap the bottle, and shake it vigorously. Adjust the suspension volume up to the red arrow mark by adding more sterile water, if necessary, and shake again. Store the reconstituted suspension in cool place.

After reconstitution, the contents should be consumed within 7 days. Keep tightly closed. Shake well before each use. Discard the unused portion after 7 days.

Contraindications

Cefixime is contraindicated in patients with a known allergy to cefixime or other cephalosporins or any of the other components of the product.

Special Warnings and Precautions for Use

Hypersensitivity Reactions

Anaphylactic/anaphylactoid reactions (including shock and fatalities) have been reported with the use of cefixime. There is some evidence of partial cross-allergenicity between the penicillins and cephalosporins. Before therapy with cefixime is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cephalosporins, penicillins or other drugs. If this product is to be given to penicillin-sensitive patients, caution should be exercised because cross-hypersensitivity among beta-lactam antibiotics has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy. If an allergic reaction to cefixime occurs, discontinue the drug.

Clostridium difficile-associated Diarrhoea

Clostridium difficile-associated diarrhoea (CDAD) has been reported with the use of nearly all antibacterial agents, including cefixime, and may range in severity from mild diarrhoea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile.

C. difficile produces toxins A and B, which contribute to the development of CDAD. Hypertoxin-producing isolates of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhoea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

Dose Adjustment in Renal Impairment

The dose of cefixime should be adjusted in patients with renal impairment as well as those undergoing CAPD and haemodialysis. Patients on dialysis should be monitored carefully.

Coagulation Effects

Cephalosporins, including cefixime, may be associated with a fall in prothrombin activity. Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilised on anticoagulant therapy. Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated.

Encephalopathy

Beta-lactams, including cefixime, predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, movement disorders), particularly in case of overdose or renal impairment.

Severe Cutaneous Adverse Reactions

Severe cutaneous adverse reactions such as toxic epidermal necrolysis, Stevens-Johnson syndrome and drug rash with eosinophilia and systemic symptoms (DRESS) have been reported in some patients on cefixime. When severe cutaneous adverse reactions occur, cefixime should be discontinued and appropriate therapy and/or measures should be taken.

Cefixime should be given with caution to patients who have shown hypersensitivity to other drugs.

Haemolytic Anaemia

Drug-induced haemolytic anaemia, including severe cases with a fatal outcome, has been described for cephalosporins (as a class). The recurrence of haemolytic anaemia after re-administration of cephalosporins in a patient with a history of cephalosporin (including cefixime)-associated haemolytic anaemia has also been reported.

Acute Renal Failure

As with other cephalosporins, cefixime may cause acute renal failure, including tubulointerstitial nephritis as an underlying pathological condition. When acute renal failure occurs, cefixime should be discontinued and appropriate therapy and/or measures should be taken.

Development of Drug-resistant Bacteria

Prescribing cefixime in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Drug Interactions

Carbamazepine

Elevated carbamazepine levels have been reported in postmarketing experience when cefixime is administered concomitantly. Drug monitoring may be of assistance in detecting alterations in carbamazepine plasma concentrations.

Warfarin and Anticoagulants

In common with other cephalosporins, increases in prothrombin times with or without clinical bleeding have been noted in a few patients. Care should, therefore, be taken in patients receiving anticoagulation therapy.

Effects on Laboratory Tests

A false-positive reaction for ketones in the urine may occur with tests using nitroprusside, but not with those using nitroferricyanide.

A false-positive reaction for glucose in the urine may occur with Benedict's or Fehling's solutions or with copper sulphate test tablets, but not with tests based on enzymatic glucose oxidase reactions.

A false-positive direct Coomb’s test has been reported during treatment with other cephalosporins; therefore, it should be recognised that a positive Coomb’s test may be due to the drug.

Use in Special Populations

Pregnancy

Pregnancy Category B

There are no adequate and well-controlled studies in pregnant women. Cefixime should, therefore, not be used in pregnancy or in nursing mothers unless considered essential by the physician.

Lactating Women

It is not known whether cefixime is excreted in human milk. Consideration should be given to discontinuing nursing temporarily during treatment with this drug.

Paediatric Patients
Safety and effectiveness of cefixime in children aged less than 6 months old have not been established. The incidence of gastrointestinal adverse reactions, including diarrhoea and loose stools, in the paediatric patients receiving the suspension was comparable with the incidence seen in adult patients receiving tablets. No data are available in case of paediatric patients with impaired renal or hepatic function.

Geriatric Patients

Clinical studies did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. A pharmacokinetic study in the elderly detected differences in pharmacokinetic parameters. These differences were small and do not indicate a need for dosage adjustment of the drug in the elderly.

Patients with Renal Impairment

The dose of cefixime should be adjusted in patients with renal impairment as well as those undergoing CAPD and haemodialysis. Patients on dialysis should be monitored carefully.

Patients with Hepatic Impairment

No data on dosing is available for patients with impaired hepatic function.

Effects on Ability to Drive and Use Machines

In the case of side effects such as encephalopathy (which may include convulsion, confusion, impairment of consciousness, movement disorders), the patient should not operate machines or drive a vehicle.

Undesirable Effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Cefixime is generally well tolerated. The majority of adverse reactions observed in clinical trials were mild and self-limiting in nature.

The listed adverse reactions mentioned below have been observed during clinical studies and/or during marketed use.

Blood and Lymphatic System Disorders

Eosinophilia

Hypereosinophilia

Agranulocytosis

Leucopaenia

Neutropaenia

Granulocytopaenia

Haemolytic anaemia

Thrombocytopaenia

Thrombocytosis

Gastrointestinal Disorders

Abdominal pain

Diarrhoea*

Dyspepsia

Nausea

Vomiting

Flatulence

Hepatobiliary Disorders

Jaundice

Infections and Infestations

Pseudomembranous colitis

Investigations

Aspartate aminotransferase increased

Alanine aminotransferase increased

Blood bilirubin increased

Blood urea increased

Blood creatinine increased

Nervous System Disorders

Dizziness

Headache

Cases of convulsions have been reported with cephalosporins, including cefixime (frequency not known)**

Beta-lactams, including cefixime, predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, movement disorders), particularly in case of overdose or renal impairment (frequency not known)**

Respiratory, Thoracic and Mediastinal Disorders

Dyspnoea

Renal and Urinary Disorders

Renal failure acute, including tubulointerstitial nephritis as an underlying pathological condition

Immune System Disorders, Administrative Site Conditions, Skin and Subcutaneous Tissue Disorders

Anaphylactic reaction

Serum sickness-like reaction

DRESS

Pruritus

Rash

Drug fever

Arthralgia

Erythema multiforme

Stevens-Johnson syndrome

Toxic epidermal necrolysis

Angio-oedema

Urticaria

Pyrexia

Face oedema

Genital pruritus

Vaginitis

*Diarrhoea has been more commonly associated with higher doses. Some cases of moderate-to-severe diarrhoea have been reported; this has occasionally warranted cessation of therapy. Cefixime should be discontinued if marked diarrhoea occurs.

** Cannot be estimated from available data

Postmarketing Experience

The following adverse reactions have been reported following the use of cefixime. Incidence rates were less than 1 in 50 (less than 2%).

  • Gastrointestinal: Several cases of documented pseudomembranous colitis were identified in clinical trials. The onset of pseudomembranous colitis symptoms may occur during or after therapy.
  • Hypersensitivity Reactions: Anaphylactic/anaphylactoid reactions (including shock and fatalities), skin rashes, urticaria, drug fever, pruritus, angio-oedema, and facial oedema. erythema multiforme, Stevens-Johnson syndrome, and serum sickness-like reactions have been reported.
  • Hepatic: Transient elevations in SGPT, SGOT, alkaline phosphatase, hepatitis, and jaundice.
  • Renal: Transient elevations in BUN or creatinine, acute renal failure.
  • Central Nervous System: Headaches, dizziness, seizures.
  • Haemic and Lymphatic System: Transient thrombocytopaenia, leucopaenia, neutropaenia, prolongation in prothrombin time, elevated LDH, pancytopaenia, agranulocytosis, and eosinophilia.
  • Abnormal Laboratory Tests: Hyperbilirubinaemia.

Other Adverse Reactions

Genital pruritus, vaginitis, candidiasis, toxic epidermal necrolysis. Spontaneous reported cases of acute generalised exanthematous pustulosis (AGEP) associated with the treatment using cefixime deduce that there is a potential risk for systemic involvement in patients with AEGP. 

Adverse Reactions Reported for Cephalosporin-class Drugs

Allergic reactions, superinfection, renal dysfunction, toxic nephropathy, hepatic dysfunction, including cholestasis, aplastic anaemia, haemolytic anaemia, haemorrhage, and colitis.

Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.

Reporting of Suspected Adverse Reactions

If you experience any side effects, talk to your doctor or pharmacist or write to drugsafety@cipla.com. You can also report side effects directly via the National Pharmacovigilance Programme (PvPI) of India by calling on 1800 267 7779 (Cipla number) or you can report to PvPI on 1800 180 3024. By reporting side effects, you can help provide more information on the safety of this product.

Overdose

There is no experience with overdoses with cefixime. Gastric lavage may be indicated; otherwise, no specific antidote exists. Cefixime is not removed in significant quantities from the circulation by haemodialysis or peritoneal dialysis. Adverse reactions in small numbers of healthy adult volunteers receiving single doses up to 2 g of cefixime did not differ from the profile seen in patients treated at the recommended doses.

Pharmacological Properties

Mechanism of Action

As with other cephalosporins, the bactericidal action of cefixime results from inhibition of cell wall synthesis. Cefixime is stable in the presence of certain beta-lactamase enzymes. As a result, certain organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases may be susceptible to cefixime.

Pharmacodynamic Properties

Pharmacotherapeutic group: third generation cephalosporin, ATC code: J01DD08

Cefixime is an oral third-generation cephalosporin that has marked in vitro bactericidal activity against a wide variety of Gram-positive and Gram-negative organisms.

Clinical efficacy has been demonstrated in infections caused by commonly occurring pathogens, including Streptococcus pneumoniae, Streptococcus pyogenes, Escherichia coli, Proteus mirabilis, Klebsiella species, Haemophilus influenzae (beta-lactamase-positive and -negative), Branhamella catarrhalis (beta-lactamase-positive and -negative) and Enterobacter species. It is highly stable in the presence of beta-lactamase enzymes.

Resistance

Resistance to cefixime in isolates of Haemophilus influenzae and Neisseria gonorrhoeae is most often associated with alterations in penicillin-binding proteins (PBPs). Cefixime may have limited activity against Enterobacteriaceae-producing extended-spectrum beta-lactamases (ESBLs). Pseudomonas species, Enterococcus species, strains of Group D streptococci, Listeria monocytogenes, most strains of staphylococci (including methicillin-resistant strains), most strains of Enterobacter species, most strains of Bacteroides fragilis, and most strains of Clostridium species are resistant to cefixime.

Antimicrobial Activity

Cefixime has been shown to be active against most isolates of the following bacteria both in vitro and in clinical infections:

Gram-positive Bacteria

Streptococcus pneumoniae

Streptococcus pyogenes

Gram-negative Bacteria

Haemophilus influenzae (beta-lactamase-positive and -negative)

Moraxella catarrhalis

Escherichia coli

Proteus mirabilis

Neisseria gonorrhoeae

Also, clinical efficacy has been demonstrated in infections caused by commonly occurring pathogens, including Branhamella catarrhalis (beta-lactamase-positive and -negative) and Enterobacter species.

The following in vitro data are available, but their clinical significance is unknown. At least 90% of the following bacteria exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for cefixime against isolates of similar genus or organism group. However, the efficacy of cefixime in treating clinical infections caused by these bacteria has not been established in adequate and well-controlled clinical trials.

Gram-positive Bacteria

Streptococcus agalactiae

Gram-negative Bacteria

Citrobacter amalonaticus

Citrobacter diversus

Haemophilus parainfluenzae

Klebsiella oxytoca

Klebsiella pneumoniae

Pasteurella multocida

Proteus vulgaris

Providencia species

Salmonella species

Serratia marcescens

Shigella species

Pharmacokinetic Properties

The absolute oral bioavailability of cefixime is in the range of 22–54%. Absorption is not significantly modified by the presence of food. Cefixime may, therefore, be given without regard to meals.

From in vitro studies, serum or urine concentrations of 1 mcg/mL or greater were considered to be adequate for most common pathogens against which cefixime is active. Typically, the peak serum levels following the recommended adult or paediatric doses are between 1.5 and 3 mcg/mL. Little or no accumulation of cefixime occurs following multiple dosing.

The pharmacokinetics of cefixime was evaluated in healthy elderly (age >64 years) and young volunteers (age 11–35 years) by comparing the administration of 400 mg doses once daily for 5 days. Mean Cmax and AUC values were slightly greater in the elderly. Elderly patients may be given the same dose as the general population.

Cefixime is predominantly eliminated as unchanged drug in the urine. Glomerular filtration is considered the predominant mechanism. Metabolites of cefixime have not been isolated from human serum or urine.

Serum protein-binding is well characterised for human and animal sera; cefixime is almost exclusively bound to the albumin fraction, the mean free fraction being approximately 30%. Protein-binding of cefixime is only concentration-dependent in human serum at very high concentrations, which are not seen following clinical dosing.

Transfer of 14C-labelled cefixime from lactating rats to their nursing offspring through breast milk was quantitatively small (approximately 1.5% of the mothers' body content of cefixime in the pup). No data are available on secretion of cefixime in human breast milk. Placental transfer of cefixime was small in pregnant rats dosed with labelled cefixime.

Non-Clinical Properties

Lifetime studies in animals to evaluate carcinogenic potential have not been conducted. Cefixime did not cause point mutations in bacteria or mammalian cells, DNA damage, or chromosome damage in vitro and did not exhibit clastogenic potential in vivo in the mouse micronucleus test. In rats, fertility and reproductive performance were not affected by cefixime at doses up to 25 times the adult therapeutic dose.

Description

Cefixime is a semisynthetic, cephalosporin antibacterial for oral administration. Chemically, it is (6R,7R)-7--8-oxo-3-vinyl-5-thia-1-azabicyclo oct-2-ene-2-carboxylic acid, 72-(Z)- trihydrate.

Molecular weight = 507.50 as the trihydrate. Chemical formula is C16H15N5O7S2.3H2O

Pharmaceutical Particulars

Incompatibilities

Not applicable.

Shelf-Life

As on the pack.

Packaging Information

OMNIX-50 DT: Strip pack of 10 dispersible tablets

OMNIX-100 DT: Strip pack of 10 dispersible tablets

OMNIX-200 DT: Strip pack of 10 dispersible tablets

OMNIX-50 Dry Syrup: Bottle of 30 mL dry syrup

OMNIX-100 Dry Syrup: Bottle of 30 mL dry syrup

Storage and Handling Instructions

OMNIX DT

Store in a cool, dry place. Protect from light.

OMNIX Dry Syrup

Before Opening

Store below 25°C. Protect from light.

After Reconstitution

The contents should be consumed within 7 days. Keep the bottle tightly closed. Shake well before each use. Discard the unused portion after 7 days.

Patient Counselling Information

What is OMNIX DT/Dry Syrup and what is it used for?

OMNIX DT/Dry Syrup contains a medicine called cefixime. This belongs to a group of antibiotics called ‘cephalosporins’. OMNIX DT/Dry Syrup is used to treat infections caused by bacteria.

● Do not take if you have an allergy to this drug

Do not take if you are allergic to cefixime, any other cephalosporin antibiotics including penicillin or to any of the other ingredients of this medicine.

Signs of an allergic reaction include a rash, swallowing or breathing problems, swelling of the lips, face, throat and tongue.

Do not take this medicine if the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking this medicine.

● Before you take OMNIX DT/Dry Syrup, tell your HCP about other medication

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines you buy without a prescription, including herbal medicines. This is because OMNIX DT/Dry Syrup can affect the way some other medicines work. Also, some medicines can affect the way OMNIX DT/Dry Syrup works.

In particular, tell your doctor if you are taking the following:

• Medicines to thin the blood such as warfarin.

● How to take OMNIX DT/Dry Syrup

Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

• Take this medicine by mouth

• If you feel the effect of the medicine is too weak or too strong, do not change the dose yourself, but ask your doctor. Carefully read the label from the pharmacist. Ask your pharmacist if you are not sure about the dose to take. The medicine should be taken for the prescribed number of days.

If you take more OMNIX DT/Dry Syrup than you should: If you have too much of this medicine, talk to your doctor straight away.

If you forget to take OMNIX DT/Dry Syrup: If you forget to take a dose, take it as soon as you remember it. However, if it is nearly time for the next dose, skip the missed dose. Do not take a double dose to make up for a forgotten dose.

If you stop taking OMNIX DT/Dry Syrup: Do not stop taking this medicine without talking to your doctor. You should not stop taking this medicine just because you feel better. This is because the infection may come back or get worse again

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

● What are the possible side effects?

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Tell your doctor straightaway or go to the nearest hospital casualty department if you notice any of the following serious side effects – you may need urgent medical treatment:

• You have an allergic reaction. The signs may include a rash, joint pain, swallowing or breathing problems, swelling of your lips, face, throat or tongue

• Blistering or bleeding of the skin around the lips, eyes, mouth, nose and genitals. Also flu-like symptoms and fever. This may be something called ‘Stevens-Johnson syndrome’.

• Severe blistering rash where layers of the skin may peel off to leave large areas of raw exposed skin over the body. Also a feeling of being generally unwell, fever, chills and aching muscles. This may be something called ‘toxic epidermal necrolysis’.

• You have a skin rash or skin lesions with a pink/red ring and a pale centre that may be itchy, scaly or filled with fluid. The rash may appear especially on the palms or soles of your feet. These could be signs of a serious allergy to the medicine called ‘erythema multiforme’.

• You get infections more easily than usual. This could be because of a blood disorder. This normally gets better after stopping the medicine. You may also bruise or bleed more easily than normal. This could be because of a blood disorder. This normally gets better after stopping the medicine.

• If your child gets nose bleeds, bleeding gums, chills, tiredness, pale skin (often with a yellow tinge), and shortness of breath. This may be due to haemolytic anaemia.

• Changes in the way the kidneys are working or blood in your child’s urine.

• Fits (convulsions) – frequency not known

• A brain condition with symptoms including fits (convulsions), feeling confused, feeling less alert or aware of things than usual, unusual muscle movements or stiffness. This may be something called ‘encephalopathy’. This side effect is more likely if you have taken an overdose or you already have a problem with your kidneys.

Stop taking this medicine and contact your doctor without delay if you get

• severe watery diarrhoea that will not stop and you are feeling weak and have a fever. This may be something called ‘pseudomembranous colitis’.

Tell your doctor or pharmacist if any of the following side effects get serious or lasts longer than a few days:

• Feeling sick (nausea) or being sick (vomiting)

• Stomach pains, indigestion or wind

• Headaches

• Feeling dizzy

• Feeling itchy in the genital or vaginal area Tell your doctor if any of the side effects gets serious or lasts longer than a few days, or if you notice any side effects not listed in this leaflet.

Blood tests

OMNIX DT/Dry Syrup can cause blood clots or small changes to the way the liver and kidneys work. This would be seen in blood tests. This is not common and goes back to normal after stopping this medicine.

Reporting of side effects

If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.

● How should I store OMNIX DT/Dry Syrup?

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date (which is stated on the label and blister pack after EXP:). Store below 25°C.

Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

● General information about the safe and effective use of this drug

Talk to your doctor or pharmacist before taking OMNIX DT/Dry Syrup

  • if you have ever had colitis
  • if you have kidney problems

If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking this medicine.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Driving and using machines

This medicine can cause symptoms including fits (convulsions), feeling confused, feeling less alert or aware of things than usual, unusual muscle movements or stiffness. If you experience any of these effects don’t drive or use machinery.

Medical tests

If you require any tests (such as blood or urine tests) while taking OMNIX DT/Dry Syrup, please make sure your doctor knows that you are taking this medicine.

● Any other information

Not applicable.

Details of the Manufacturer

Mfd. By Cipla Ltd.

Registered Office:

Cipla House, Peninsula Business Park,

Ganpatrao Kadam Marg

Lower Parel

Mumbai – 400 013, India

Details of Permission or Licence Number with Date

OMNIX-50 DT, OMNIX-100 DT and OMNIX-200 DT

M.L. PD/135 dated 05/03/2018

OMNIX-50 Dry Syrup and OMNIX-100 Dry Syrup

M.L. PD-475-A dated 03/02/2015

Date of Revision

26-12-2019